Neothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat
June 26, 2017 08:00 ET | Neothetics, Inc.
SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced...
Neothetics Provides Business Update and Reports First Quarter 2017 Financial Results
May 11, 2017 08:00 ET | Neothetics, Inc.
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a...
Neothetics to Provide a Business Update and Release First Quarter 2017 Financial Results Thursday, May 11th, 2017
May 04, 2017 08:00 ET | Neothetics, Inc.
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, announced today...
Neothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical Asset
April 05, 2017 08:00 ET | Neothetics, Inc.
SAN DIEGO, April 05, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced the...
Neothetics to Present at the 16th Annual Needham Healthcare Conference
March 29, 2017 08:00 ET | Neothetics, Inc.
SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that Susan A. Knudson, Neothetics’ Chief Financial Officer, will present at the 16th Annual Needham...
Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results
March 23, 2017 08:00 ET | Neothetics, Inc.
SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016. “We are encouraged by our...
Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
March 20, 2017 08:00 ET | Neothetics, Inc.
SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced...
Neothetics to Provide a Business Update and Release Fourth Quarter 2016 Financial Results Thursday, March 23, 2017
March 16, 2017 08:00 ET | Neothetics, Inc.
SAN DIEGO, March 16, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that it will provide a business update and release its fourth quarter 2016 financial results before the...
Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
December 23, 2016 08:00 ET | Neothetics, Inc.
SAN DIEGO, Dec. 23, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced the initiation of the Phase 2 proof of concept trial, LIPO-202-CL-31, for LIPO-202 for the reduction of...
Neothetics Provides Business Update and Reports Third Quarter 2016 Financial Results
November 10, 2016 08:00 ET | Neothetics, Inc.
SAN DIEGO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update on its strategic initiatives and reported financial results for the third quarter 2016. ...